Previous Article | Next Article ![]()
Infection and Immunity, November 2000, p. 6294-6299, Vol. 68, No. 11
Department of Medicine, Weill Medical College
of Cornell University, New York, New York 10021
Received 12 June 2000/Returned for modification 21 July
2000/Accepted 14 August 2000
In experimental visceral leishmaniasis, acquired resistance to
intracellular Leishmania donovani is Th1 cell cytokine
dependent and largely mediated by gamma interferon (IFN- The peripheral blood monocyte
appears to play a particularly important host defense role in
experimental visceral leishmaniasis, a disseminated intracellular
protozoal infection in which resident tissue macrophages are the
primary targets (3, 19, 22). Blockade of monocyte influx,
achieved by treating Leishmania donovani-infected mice with
a monoclonal antibody (MAb) directed at the The present report extends the analysis of the host defense role of the
infiltrating monocyte and monocyte-directed granuloma assembly to this
cell's action in the response to antileishmanial chemotherapy. In
contrast to two other agents now in clinical use, amphotericin B and
miltefosine (18, 23, 24), the in vivo leishmanicidal
efficacy of pentavalent antimony (Sb), the conventional treatment for
visceral leishmaniasis (25), requires an intact host T-cell
(Th1 cell)-dependent response. Thus far, characterization of this
mechanism indicates obligatory roles for T cells and a cytokine network
involving endogenous interleukin 12 (IL-12), IFN- The latter two inflammatory cytokines are well recognized in activation
of both monocytes and resident macrophages to express enhanced
antileishmanial effects (22, 23, 26, 31, 40, 41). However,
these same cytokines also influence monocyte trafficking in the
microcirculation and transendothelial cell migration (7-9, 38) and thus help to deliver these effector phagocytes into infected tissue sites and foster granuloma assembly (26,
40). These events appear largely regulated via initial
endothelial cell adhesion mechanisms including chemokine-induced
effects (1, 14) and upregulation of intracellular adhesion
molecule 1 (ICAM-1), the principal endothelial cell counter-receptor
for monocyte-expressed Mac-1 (8, 38). Given the critical
actions of the blood monocyte in the L. donovani model
(described above) (3), its role as a target for IFN- Animals.
Mice with ICAM-1 gene disruptions, on a C57BL/6
background (37), were purchased as breeders from The Jackson
Laboratory (Bar Harbor, Maine). These mice express three mutant
isoforms of ICAM-1 (13), a state which impairs binding to
Mac-1 (resulting in monocytes being unable to leave the
microcirculation [11]) but apparently does not
interfere with binding to the T-cell-expressed Visceral infection and granuloma development.
Groups of
three to five mice were injected via the tail vein with 1.5 × 107 hamster spleen-derived L. donovani
amastigotes (1 Sudan strain) (23). Visceral infection was
monitored microscopically using Giemsa-stained liver imprints in which
liver parasite burdens were measured by counting the number of
amastigotes per 500 cell nuclei and multiplying by the liver weight in
milligrams (Leishman-Donovan units [LDU]) (23). The
granulomatous response to infection in the liver was assessed in
histologic sections stained with hematoxylin and eosin. Granuloma
formation was scored as follows: (i) none Antibiotic treatment.
Two weeks after infection (day 0),
liver parasite burdens were determined, and mice then received either
no treatment, a single intraperitoneal (i.p.) injection of Sb, three
i.p. injections of amphotericin B deoxycholate (AmB), or five
consecutive once-daily doses of oral miltefosine by gavage (23,
24). Optimal doses of each drug were administered: Sb (sodium
stibogluconate, Pentostam; Wellcome Foundation Ltd., London, United
Kingdom), 500 mg/kg of body weight on day 0; AmB (Gensia Laboratories
Ltd., Irvine, Calif.), 5 mg/kg on days 0, +2, and +4; and miltefosine
(ASTA Medica AG, Frankfurt, Germany), 25 mg/kg on days 0 to +4
(23, 24). Seven days after treatment was started (day +7),
all mice were sacrificed and liver parasite burdens were measured.
Percent parasite killing was determined as (day 0 LDU IFN- Initial kinetics and outcome of visceral infection.
In control
C57BL/6 mice, liver parasite burdens peaked at week 2 and then rapidly
declined (Fig. 1) as these normal animals promptly acquired resistance and killed L. donovani
(23). In contrast, in mice with ICAM-1 gene disruptions,
visceral infection progressed after week 2, yielding liver burdens
which were ninefold higher at week 4 than those in controls.
Subsequently, however, mutant animals altered their behavior,
controlled intracellular replication, and reduced visceral infection,
albeit in an incomplete fashion (Fig. 1).
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mononuclear Cell Recruitment, Granuloma Assembly,
and Response to Treatment in Experimental Visceral Leishmaniasis:
Intracellular Adhesion Molecule 1-Dependent and -Independent
Regulation
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
); the same
response also permits conventional antimony (Sb) chemotherapy to
express its leishmanicidal effect. Since the influxing blood monocyte (which utilizes endothelial cell ICAM-1 for adhesion and tissue entry)
is a primary effector target cell for this cytokine mechanism, we
tested the monocyte's role in host responsiveness to chemotherapy in
mice with ICAM-1 gene disruptions. Mutant animals failed to develop any
early granulomatous tissue response in the liver, initially supported
high-level visceral parasite replication, and showed no killing after
Sb treatment; the leishmanicidal response to a directly acting,
alternative chemotherapeutic probe, amphotericin B, was intact.
However, mutant mice proceeded to express a compensatory, ICAM-1-independent response leading to mononuclear cell influx and
granuloma assembly, control over visceral infection, and the capacity
to respond to Sb. Together, these results point to the recruitment of
emigrant monocytes and mononuclear cell granuloma formation, mediated
by ICAM-1-dependent and -independent pathways, as critical determinants
of host responsiveness to conventional antileishmanial chemotherapy.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2 integrin, type 3 complement receptor (CR3, CD11b/CD18, Mac-1), deprived parasitized tissues of this effector cell and initially impaired three
interrelated mechanisms: granuloma formation, the capacity to respond
to gamma interferon (IFN-
) with intracellular parasite killing, and
acquired resistance (3). Conversely, treating mice with
granulocyte-macrophage colony-stimulating factor induced myelomonocytic
cell influx into the tissues, strikingly enhanced granuloma formation
at infected foci, and resulted in parasite killing (20).
, and tumor
necrosis factor (TNF) (17, 23, 26, 27).
and
TNF (22), and its additional capacity to accumulate Sb
(16), we hypothesized that the monocyte also regulates host
responsiveness to Sb chemotherapy. To test this possibility, we
infected mice deficient in ICAM-1, characterized mononuclear cell
influx and granuloma formation, and then administered antileishmanial treatment.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2
integrin, lymphocyte function antigen 1 (LFA-1) (11), or with the interaction of LFA-1 with other endothelial cell ligands (e.g., ICAM-2 and ICAM-3 [29, 33, 38]) (4, 11,
39). Normal C57BL/6 mice weighing 20 to 30 g (Jackson
Laboratory) were used as controls. Mice with gene disruptions were both
male and female; normal mice were female. Animals were 8 to 15 weeks
old when challenged with L. donovani.
single or fused parasitized
Kupffer cells with no mononuclear cell infiltrate; (ii)
developing
some cellular infiltrate at the parasitized focus; (iii)
mature
a core of fused infected Kupffer cells surrounded by a
well-developed mononuclear cell mantle (3, 22).
day +7
LDU in treated mice)/(day 0 LDU) × 100 (23). In some
experiments, visceral infection was allowed to progress to week 4 or
week 8 before Sb treatment was given, and the same evaluation was
performed. Differences in liver parasite burdens were analyzed using a
two-tailed Student's t test.
measurement.
Serum IFN-
activity was measured by
an enzyme-linked immunosorbent assay (ELISA) (Endogen, Cambridge,
Mass.) with a detection limit of 50 pg/ml (40).
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (15K):
[in a new window]
FIG. 1.
Course of L. donovani infection in livers of
normal C57BL/6 mice (open circles) and mice with ICAM-1 gene
disruptions (solid circles). Results (mean LDU ± standard errors
of the means at weeks 2, 4, and 8 are from three experiments
(n = 9 to 11 mice per group), one of which was extended
to week 12 in ICAM-1-deficient animals (n = 4 mice).
P < 0.05 for mutant versus control mice at weeks 4 and
8.
Granuloma assembly.
Two weeks after challenge, 92% of
infected liver foci in control C57BL/6 mice had attracted mononuclear
cells; histologic scoring indicated developing granulomas at
69 ± 5% of foci and mature granulomas at 23 ± 4% (Table
1; Fig.
2a). By week 4 (Fig. 2b), 70% of
parasitized foci were composed of either mature or "empty"
granulomas (structures devoid of visible amastigotes); by week 8, three-quarters of the tissue cellular collections in normal mice were
parasite free.
|
|
Response to chemotherapy.
To determine if monocyte influx and
initial granuloma formation altered the response to chemotherapy,
2-week-infected mice were treated with AmB, miltefosine, or Sb
using established protocols (23, 24). ICAM-1-mutant mice
responded to AmB with high-level leishmanicidal activity (Table
2). In a single experiment, these animals
also responded to oral miltefosine, showing 71% L. donovani killing 7 days after treatment began versus 81% killing in C57BL/6 controls (n = 3 mice per group) (data not shown).
However, while normal mice reduced liver parasite burdens by 85% after
a single injection of Sb (500 mg/kg), ICAM-1-deficient animals showed
only 3% killing after the same treatment (Table 2). To exclude an altered dose response, 2-week-infected ICAM-1 mutants were also given
high-dose Sb (three injections of 500 mg/kg on alternate days). Mutant
animals also failed to respond to this regimen with meaningful
leishmanicidal activity (8% killing).
|
Restoration of responsiveness to Sb. The observation that ICAM-1-deficient mice expressed a compensatory, although less efficient, pathway for mononuclear cell recruitment provided a separate opportunity to test the relationship between monocyte influx and granuloma assembly and responsiveness to Sb. Since granuloma development in 4-week-infected mutant mice appeared roughly comparable to that in 2-week-infected, Sb-responsive C57BL/6 mice (Table 1), we hypothesized that Sb-induced leishmanicidal activity should be expressed by week 4 despite disruption of ICAM-1. Results from two experiments (Table 2), in which mutant mice were treated with a single dose of Sb (500 mg/kg) at week 4, supported this hypothesis: liver parasite burdens were reduced by 68% in response to the same Sb regimen which produced only 3% killing in 2-week-infected gene-deficient mice. In addition, in a single experiment, in which treatment of ICAM-1-deficient animals was delayed to week 8, at a time when the majority of infected liver foci were comprised of mature or empty granulomas (Table 1), the response to a single injection of Sb appeared to be accentuated further (Table 2). While liver parasite burdens declined by 11% in untreated mice during the 7-day observation period, Sb-treated mutant mice showed an 81% decrease.
IFN-
production.
ICAM-1 may also act in a
T-cell-costimulatory mechanism via LFA-1 (12, 28, 35-37,
42); thus, ICAM-1-deficient mice might have failed to respond to
Sb because of defective cytokine production, in particular, defective
IFN-
secretion. T-cell-derived IFN-
, another endogenous cofactor
required for Sb's killing effect (23), likely supports
Sb's action by enhancing monocyte tissue recruitment (e.g., via
upregulation of ICAM-1 [7, 8, 14, 38]), attracting T
cells (10, 14, 21, 34), activating recruited monocytes to
exert intracellular antileishmanial effects (3, 22), and/or stimulating monocyte uptake of Sb (16). However, there was
no defect in IFN-
production in mice with ICAM-1 gene disruptions, since levels in the sera of 2-week-infected animals (502 ± 149 pg/ml) were comparable to those in normal mice (423 ± 96 pg/ml) (two experiments; n = 4 mice per group); levels in
uninfected mice in both groups were undetectable (<50 pg/ml;
n = 5 mice per group). These results, consistent with
intact IFN-
(and IL-12) mRNA induction reported in the same
ICAM-1-deficient mice infected with Mycobacterium
tuberculosis (11), presumably reflect preserved binding
sites for LFA-1 (11) or the presence of redundant T-cell costimulation mechanisms (4, 39) in L. donovani-infected mice.
| |
DISCUSSION |
|---|
|
|
|---|
The results of this study suggest that well-recognized ICAM-1-dependent events, firm endothelial cell-leukocyte adhesion and transendothelial cell migration (8, 11, 37, 38), likely regulate the initial host defense action of blood monocytes in L. donovani-infected tissues and in turn the capacity to respond to Sb chemotherapy. Since neutrophils and natural killer (NK) cells (but not T cells) also express Mac-1 (CR3) (3, 38), their adhesion to activated endothelium and entry into tissue via ICAM-1 would also likely be impaired or absent in ICAM-1-deficient mice (6, 37). However, neutrophils are seldom found at week 2 or beyond in L. donovani-infected sites, and NK cells are not required for either granuloma formation or control over parasite replication in the liver (3, 22). Thus, we interpreted observations made in infected ICAM-1-deficient mice as primarily reflecting effects of inhibition of blood monocyte entry into parasitized tissue.
In the absence of early monocyte recruitment at week 2 (Fig. 2c), three
principal effects were observed. (i) First, liver granuloma assembly,
including monocyte-induced attraction of other key mononuclear
cells (e.g., T cells [1, 3, 5, 14]), failed. Since
LFA-1 binding sites are preserved in these ICAM-1-mutant mice
(11), we anticipated little impairment in T-cell influx. However, the inability of monocytes to enter the infected focus and
elaborate or induce local release of T-cell-attracting factors including chemokines (e.g., IFN-
-inducible protein 10) (5, 14) may have contributed to the initial failure to recruit any mononuclear cells. It is possible that parasitized resident macrophages (Kupffer cells) also provided some level of chemoattractant signals; however, Kupffer cells do not express CR3 (32), and we made the same histologic observations in normal mice treated with anti-CR3 to block only monocyte influx (3). (ii) Second, in the
absence of monocyte recruitment, intracellular infection progressed.
(iii) Third, under these conditions, the host capacity to express Sb's leishmanicidal action was abolished.
The effect on host responsiveness to Sb chemotherapy was clear,
therefore adding ICAM-1 and influxing blood monocytes to the complex T
cell/Th1 cell-derived cytokine mechanism which determines Sb's
efficacy in vivo (17, 23, 26, 27). However, responses to AmB
and miltefosine in mutant mice were entirely preserved. Intact efficacy
of these two alternative antileishmanial agents in the absence of
monocyte recruitment and granuloma formation is quite consistent with
their apparently direct killing action. AmB and miltefosine, for
example, retain full experimental leishmanicidal effects in the host
devoid of mature T cells or lacking activating, pro-host defense
cytokines including IFN-
, IL-12, and TNF (18, 23, 24, 26,
27).
Although ICAM-1 was an essential participant early on in this model,
the strict requirement for its presence in initiating granuloma
assembly and defense against visceral L. donovani in the liver proved to be relatively short-lived (Fig. 1 and 2). Our
experiments did not address the nature of the slowly developing, late-onset compensatory mechanism(s) which emerged in mice with gene
disruptions to induce mononuclear cell influx and granuloma formation
with control over parasite replication. However, CR3- and
ICAM-1-independent monocyte recruitment to infected tissues has been
well reported (3, 6, 30, 32). Binding of very late antigen 4 (VLA-4), a surface
1 integrin expressed on
monocytes, to its endothelial cell ligand, vascular cell adhesion
molecule 1 (VCAM-1), for example, can mediate ICAM-1-independent
endothelial cell adhesion, monocyte migration, and granuloma
formation (2, 30). Other similarly acting pathways available
to ICAM-1-deficient mice may include responses via ICAM-2 and ICAM-3
(2, 38).
Once monocyte influx with early granuloma formation was established at week 4 in ICAM-1 mutants, responsiveness to Sb treatment was also restored. While this result underscored the role of monocyte influx/granuloma assembly in the expression of Sb's leishmanicidal action, the actual role of the monocyte in this mechanism needs to be defined. Possible actions include elaboration of activating monokines, attraction of cytokine-secreting Th1 cells with induction of synergistic effects from monocyte/macrophage activation (17, 23, 26, 27), intracellular accumulation and altered metabolism of Sb (16), or even monocyte activation induced by Sb itself.
At the same time, the observation that ICAM-1-deficient mice developed the capacity to respond to Sb treatment also indicated that the specific responding adhesion/recruitment mechanism (ICAM-1 versus the compensatory pathway) was not necessarily relevant as long as it properly fostered accumulation of mononuclear cells at sites of L. donovani infection. In this setting, this compensatory, ICAM-1-independent mechanism readily supported host responsiveness to Sb. Nevertheless, inspection of the data in Fig. 1, showing the persistence of visceral infection to week 8 in mice with gene disruptions, also serves to reemphasize that in addition to early control over intracellular replication, ICAM-1-dependent inflammatory events set the stage for the most efficient killing of L. donovani and optimal parasite removal.
| |
ACKNOWLEDGMENTS |
|---|
I am grateful to William Muller (Department of Pathology, Weill Medical College) for helpful advice about the histologic results and to C. Montelibano for technical assistance.
This work was supported by NIH research grant AI 16963.
| |
FOOTNOTES |
|---|
* Mailing address: Department of Medicine, Weill Medical College of Cornell University, 1300 York Ave., Box 136, New York, NY 10021. Phone: (212) 746-6330. Fax: (212) 746-6332. E-mail: hwmurray{at}med.cornell.edu.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Adams, D. H., and A. R. Lloyd. 1997. Chemokines: leukocyte recruitment and activation cytokines. Lancet 349:490-495[CrossRef][Medline]. |
| 2. |
Anderson, D. C.
1995.
The role of 2 integrins and intracellular adhesion molecule 1 in inflammation, p. 3-42.
In
D. N. Granger, and G. W. Schmid-Schonbein (ed.), Physiology and pathophysiology of leukocyte adhesion. Oxford University Press, New York, N.Y.
|
| 3. |
Cervia, J.,
H. Rosen, and H. Murray.
1993.
Effector role of blood monocytes in experimental visceral leishmaniasis.
Infect. Immun.
61:1330-1333 |
| 4. |
Christensen, J. P.,
O. Marker, and A. R. Thomsen.
1996.
T-cell-mediated immunity to lymphocytic choriomeningitis virus in 2-integrin (CD18)- and ICAM-1 (CD54)-deficient mice.
J. Virol.
70:8997-9002[Abstract].
|
| 5. | Cotterell, S. E., C. R. Engwerda, and P. M. Kaye. 1999. Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur. J. Immunol. 29:203-214[CrossRef][Medline]. |
| 6. | Davis, S. L., E. P. Hawkins, E. O. Mason, C. W. Smith, and S. L. Kaplan. 1996. Host defenses against disseminated candidiasis are impaired in intracellular adhesion molecule 1-deficient mice. J. Infect. Dis. 174:435-439[Medline]. |
| 7. | Dustin, M. L., R. Rothlein, A. K. Bhan, C. A. Dinarello, and T. A. Springer. 1986. A natural adherence molecule (ICAM-1): induction by IL-1 and interferon-gamma, tissue distribution, biochemistry, and function. J. Immunol. 137:245-254[Abstract]. |
| 8. |
Etzioni, A.
1994.
Adhesion molecules in host defense.
Clin. Diagn. Lab Immunol.
1:1-4 |
| 9. | Henninger, D. D., J. Panes, M. Eppihimer, J. Russell, M. Gerritsen, D. C. Anderson, and D. N. Granger. 1997. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J. Immunol. 158:1825-1832[Abstract]. |
| 10. |
Isselkutz, T. B.,
J. M. Stolz, and P. V. D. Meide.
1988.
Lymphocyte recruitment in delayed-type hypersensitivity: the role of IFN- .
J. Immunol.
140:2989-2995[Abstract].
|
| 11. |
Johnson, C. M.,
A. M. Cooper,
A. A. Frank, and I. M. Orme.
1998.
Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene.
Infect. Immun.
66:1666-1670 |
| 12. |
Kim, J. J.,
T. Anthony,
L. K. Nottingham,
L. Morrison,
D. M. Cunning,
J. Oh,
D. J. Lee,
K. Dang,
T. Dentchev,
A. A. Chalian,
M. G. Agadjanyan, and D. B. Weiner.
1999.
Intracellular adhesion molecule-1 modulates 2-chemokines and directly costimulates T cells in vivo.
J. Clin. Investig.
103:869-877[Medline].
|
| 13. | King, P. D., E. T. Sandberg, A. Selvakumar, P. Feng, A. L. Beaudet, and B. Dupont. 1995. Novel isoforms of murine intracellular adhesion molecule-1 generated by alternative RNA splicing. J. Immunol. 154:6080-6093[Abstract]. |
| 14. |
Luster, A. D.
1998.
Chemokines chemotactic cytokines that mediate inflammation.
N. Engl. J. Med.
338:436-445 |
| 15. |
Mielke, M. E. A.,
G. Niedobitek,
H. Stein, and H. Hahn.
1989.
Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions.
J. Exp. Med.
170:589-594 |
| 16. |
Murray, H. W.,
J. D. Berman, and S. D. Wright.
1988.
Immunochemotherapy for intracellular Leishmania donovani infection: interferon- plus pentavalent antimony.
J. Infect. Dis.
157:973-979[Medline].
|
| 17. | Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J. Clin. Investig. 83:1254-1259. |
| 18. |
Murray, H. W.,
J. Hariprashad, and R. Fichtl.
1993.
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.
Antimicrob. Agents Chemother.
37:1504-1505 |
| 19. | Murray, H. W. 1994. Blood monocytes: differing effector roles in experimental visceral vs. cutaneous leishmaniasis. Parasitol. Today 10:220-223[CrossRef][Medline]. |
| 20. | Murray, H. W., J. Cervia, J. Hariprashad, A. Taylor, M. Stoeckle, and H. Hockman. 1995. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Investig. 95:1183-1189. |
| 21. |
Murray, H. W.,
J. Hariprashad,
B. Aguero, and H. Yeganeyi.
1995.
Intracellular antimicrobial response of T cell-deficient host to cytokine therapy: IFN- in experimental visceral leishmaniasis in nude mice.
J. Infect. Dis.
171:1309-1314[Medline].
|
| 22. | Murray, H. W. 1999. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis, p. 977-993. In J. I. Gallin, R. Synderman, D. T. Fearon, B. F. Haynes, and C. Nathan (ed.), Inflammation: basic principles and clinical correlates, 3rd ed. Lippincott-Raven, Philadelphia, Pa. |
| 23. |
Murray, H. W., and S. Delph-Etienne.
2000.
Role of endogenous gamma interferon and macrophage microbial mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
Infect. Immun.
68:288-293 |
| 24. | Murray, H. W., and S. Delph-Etienne. 2000. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbial mechanisms. J. Infect. Dis. 181:795-799[CrossRef][Medline]. |
| 25. | Murray, H. W. Treatment of visceral leishmaniasis: a decade of progress and future approaches. Int. J. Infect. Dis., in press. |
| 26. | Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun., in press. |
| 27. | Murray, H. W., and C. Montelibano. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis., in press. |
| 28. | Nicod, L. P., and F. El Habre. 1992. Adhesion molecules on human lung dendritic cells and their role for T-cell activation. Am. J. Respir. Cell Mol. Biol. 7:207-214. |
| 29. | Reiss, Y., G. Hoch, U. Deutsch, and B. Engelhardt. 1998. T cell interaction with ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells. Eur. J. Immunol. 28:3086-3099[CrossRef][Medline]. |
| 30. | Ritter, D. M., and J. H. McKerrow. 1996. Intracellular adhesion molecule 1 is the major adhesion molecule expressed during schistosome granuloma formation. Infect. Immun. 64:4706-4713[Abstract]. |
| 31. |
Roach, T.,
A. Kiderlen, and J. Blackwell.
1991.
Role of inorganic nitrogen oxides and TNF- in killing Leishmania donovani in gamma interferon-lipopolysaccharide-activated macrophages from LshS and LshR congenic mouse strains.
Infect. Immun.
59:3935-3944 |
| 32. | Rosen, H. 1990. Role of CR3 in induced myelomonocytic recruitment: insights from in vivo monoclonal antibody studies in the mouse. J. Leukoc. Biol. 48:465-469[Medline]. |
| 33. |
Sancho, D.,
M. Yanez-Mo,
R. Tejedor, and F. Sanchez-Madrid.
1999.
Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intracellular adhesion molecule-1 and interleukin-15.
Blood
93:886-896 |
| 34. | Schall, T. J., and K. B. Bacan. 1994. Chemokine, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 6:856-873. |
| 35. |
Semnani, R. T.,
T. B. Nutman,
P. Hochman,
S. Shaw, and G. A. van Seventer.
1994.
Costimulation by purified intracellular adhesion molecule 1 and lymphocyte function-associated antigen 3 induces distinct proliferation, cytokine and cell surface antigen profiles in human "naive" and "memory" CD4+ T cells.
J. Exp. Med.
180:2125-2135 |
| 36. | Shimizu, Y., W. Newman, Y. Tanaka, and S. Shaw. 1992. Lymphocyte interaction with endothelial cells. Immunol. Today 13:106-110[CrossRef][Medline]. |
| 37. |
Sligh, J. E.,
C. M. Ballantyne,
S. S. Rich,
H. K. Hawkins,
C. W. Smith,
A. Bradley, and A. L. Beaudet.
1993.
Inflammatory and immune responses are impaired in mice deficient in intracellular adhesion molecule 1.
Proc. Natl. Acad. Sci. USA
90:8529-8533 |
| 38. | Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314[CrossRef][Medline]. |
| 39. |
Steeber, D. A.,
M. L. Tang,
N. E. Green,
X. Q. Zhang,
J. E. Sloane, and T. F. Tedder.
1999.
Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM-1 pathways.
J. Immunol.
163:2176-2186 |
| 40. |
Taylor, A., and H. W. Murray.
1997.
Intracellular antimicrobial activity in the absence of interferon- : effect of interleukin 12 in experimental visceral leishmaniasis in interferon- gene-disrupted mice.
J. Exp. Med.
185:1231-1239 |
| 41. |
Tumang, M.,
C. Keogh,
L. Moldawer,
D. Helfgott,
J. Hariprashad, and H. W. Murray.
1994.
Role and effect of TNF- in experimental visceral leishmaniasis.
J. Immunol.
153:768-774[Abstract].
|
| 42. | Wilkes, D. S., D. Bowman, O. W. Cummings, and K. M. Heidler. 1999. Allogeneic bronchoalveolar lavage cells induce the histology and immunology of lung allograft rejection in recipient murine lungs. Transplantation 67:890-896[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»